135 related articles for article (PubMed ID: 31653561)
21. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.
Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M
Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085
[TBL] [Abstract][Full Text] [Related]
23. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
24. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates.
De Bruycker A; De Bleser E; Decaestecker K; Fonteyne V; Lumen N; De Visschere P; De Man K; Delrue L; Lambert B; Ost P
Eur Urol; 2019 May; 75(5):826-833. PubMed ID: 30503072
[TBL] [Abstract][Full Text] [Related]
25. Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer.
Quhal F; Bryniarski P; Rivas JG; Gandaglia G; Shariat SF; Rajwa P
Curr Opin Urol; 2023 Jul; 33(4):269-273. PubMed ID: 37166270
[TBL] [Abstract][Full Text] [Related]
26. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.
Knipper S; Tilki D; Mansholt J; Berliner C; Bernreuther C; Steuber T; Maurer T; Graefen M
Eur Urol Focus; 2019 Jan; 5(1):50-53. PubMed ID: 30292421
[TBL] [Abstract][Full Text] [Related]
27. Salvage lymph node dissection after
Herlemann A; Kretschmer A; Buchner A; Karl A; Tritschler S; El-Malazi L; Fendler WP; Wenter V; Ilhan H; Bartenstein P; Stief CG; Gratzke C
Oncotarget; 2017 Oct; 8(48):84180-84192. PubMed ID: 29137414
[TBL] [Abstract][Full Text] [Related]
28. Management of positive lymph nodes following radical prostatectomy.
Heidenreich A; Rieke M; Mahjoub S; Pfister D
Arch Esp Urol; 2019 Mar; 72(2):182-191. PubMed ID: 30855020
[TBL] [Abstract][Full Text] [Related]
29. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy.
Tilki D; Mandel P; Seeliger F; Kretschmer A; Karl A; Ergün S; Seitz M; Stief CG
J Urol; 2015 Feb; 193(2):484-90. PubMed ID: 25180792
[TBL] [Abstract][Full Text] [Related]
30. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
31. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
32. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
33. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.
Oderda M; Joniau S; Palazzetti A; Falcone M; Melloni G; Van Den Bossche H; Deconinck S; Zattoni F; Karnes RJ; Gontero P
Eur Urol Focus; 2018 Mar; 4(2):288-293. PubMed ID: 30205893
[TBL] [Abstract][Full Text] [Related]
34. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
[TBL] [Abstract][Full Text] [Related]
35. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
36. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection.
Osmonov DK; Aksenov AV; Trick D; Naumann CM; Hamann MF; Faddan AA; Jünemann KP
BMC Urol; 2016 Sep; 16(1):56. PubMed ID: 27601051
[TBL] [Abstract][Full Text] [Related]
37. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
[TBL] [Abstract][Full Text] [Related]
38. Salvage lymph node dissection in hormone-naïve men: How effective is surgery?
Hanske J; Ostholt J; Roghmann F; Müller G; Braun K; Gomez B; von Landenberg N; von Bodman C; Palisaar RJ; Liermann D; Noldus J; Brock M
Urol Oncol; 2019 Nov; 37(11):812.e17-812.e24. PubMed ID: 31327750
[TBL] [Abstract][Full Text] [Related]
39. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
[TBL] [Abstract][Full Text] [Related]
40. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.
Ploussard G; Gandaglia G; Borgmann H; de Visschere P; Heidegger I; Kretschmer A; Mathieu R; Surcel C; Tilki D; Tsaur I; Valerio M; van den Bergh R; Ost P; Briganti A;
Eur Urol; 2019 Oct; 76(4):493-504. PubMed ID: 30391078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
